John Reed to join Roche Pharma Research and Early Development

Takes up role as head of pRED in April

Swiss pharmaceutical manufacturer Roche has appointed John Reed as head of Roche Pharma Research and Early Development (pRED). The Genentech Research and Early Development organisation (gRED), based in South San Francisco, is not affected by this management change.

Reed will be based in Basel and take up his new role on 2 April, reporting to Severin Schwan, CEO of the Roche Group.

Schwan said Reed’s broad scientific and medical background means he is ‘ideally positioned to drive Roche’s strategy of translating a better understanding of disease mechanisms into promising therapeutics’.

Mike Burgess, currently interim head of pRED, has decided to leave the company.

Prior to joining Roche, Reed was CEO at Sanford-Burnham Medical Research Institute in La Jolla, California. He is a biomedical researcher with a focus on cancer, neuroprotection, autoimmunity, and other diseases.

You may also like

Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Research & Development

Roche's multiple sclerosis drug fenebrutinib displays positive Phase II data

The drug was able to stop a majority of patients from relapsing, while also halting disability progression in the FENopta study
Research & Development

Roche seeking to overhaul inventory management in pharmaceutical sector

Global pharma giant partners with Wazoku to tap into the expertise of its 700,000-strong crowd
Research & Development

PhoreMost partners with Roche on multi-project drug target collab

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER
Research & Development

Lab standardisation: working smarter to improve patient outcomes

We’re living in a pivotal time for healthcare, reports Benjamin Lilienfeld, LifeCycle Leader at Roche Diagnostics Solutions. An advanced understanding of diseases, innovative techniques and treatments, a dizzying array of new technologies and a growing population of empowered and knowledgeable patients and caregivers have, together, made healthcare systems increasingly complex
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Subscribe now